Chronic diarrhoea, weight loss and a positive anti-tissue transglutaminase antibody: A case report of olmesartan-induced enteropathy.
BMJ Case Rep
; 17(5)2024 May 06.
Article
em En
| MEDLINE
| ID: mdl-38719261
ABSTRACT
Olmesartan is an angiotensin II receptor blocker licensed for the treatment of hypertension. It can cause a sprue-like enteropathy (SLE), characterised by chronic diarrhoea, weight loss and villous atrophy. Transiently raised anti-tissue transglutaminase (ATTG) antibody has also been rarely reported in the literature.We describe the case of a woman in her mid-50s, who presented with a history of intermittent loose stools over 1 year, associated with significant weight loss. She had two marginally raised serum ATTG antibody tests during her work-up.After extensive investigations, she was diagnosed with olmesartan-induced enteropathy. On subsequent follow-up, her symptoms had resolved with cessation of her olmesartan therapy.This case adds to existing literature, highlighting the importance of considering olmesartan as a possible differential diagnosis for SLE. It also reports the presence of a raised ATTG antibody which is infrequently reported in this context.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Tetrazóis
/
Redução de Peso
/
Transglutaminases
/
Diarreia
/
Imidazóis
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article